Clinical trials: Moderate COVID-19-infection
SARS-CoV-2 Infection, COVID-19
An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY
This study is an adaptive, randomized, open-label, controlled clinical trial, performed worldwide in collaboration with WHO and INSERM.
- Conditions
- SARS-CoV-2 Infection, COVID-19, Moderate and Severe COVID-19
- Trial name
- NCT04575064
- Testing
- Standard of Care (SoC), Remdesivir
- Where
- 4 sites in Germany
- Sponsor
- Professor Dr. Bernd Mühlbauer
Mild to Moderate COVID-19
Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19
This study is a double-blind,randomized,placebo-controlled study to evaluate the efficacy and safety of FB2001 for Inhalation in patients with mild to moderate Coronavirus Disease 2019(COVID-19).
- Trial name
- NCT05675072
- Testing
- FB2001
- Where
- China
- Volunteers
- 1,336 people
- Sponsor
- Frontier Biotechnologies Inc.
Moderate COVID-19-infection
Viable Human SARS-CoV-2 Specific T Cell Transfer in Patients at Risk for Severe COVID-19
Monocentric open phase I (dose escalation component), followed by a multi-center, randomized, phase II component benchmarking IMP+SoC against SoC
- Trial name
- ACT-COVID-19 (NCT04762186)
- Testing
- human SARS-CoV 2 specific T lymphocytes
- Where
- Germany
- Volunteers
- 1 people
- Sponsor
- Universitätsklinikum Köln
Severe Acute Respiratory Syndrome Coronavirus 2, Coronavirus Infection
Fluvoxamine for Adults With Mild to Moderate COVID-19
This clinical trial aims to determine if fluvoxamine, a selective serotonin reuptake inhibitor with high affinity for the sigma-1 receptor, can be used in mild to moderate COVID-19 to prevent the progression to severe COVID-19.
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2, Coronavirus Infection, Mild to Moderate COVID-19
- Trial name
- NCT04711863
- Testing
- Fluvoxamine
- Where
- South Korea
- Volunteers
- 400 people
- Sponsor
- Asan Medical Center
Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19
Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection
The objectives of this intermediate-size expanded access protocol are to assess the safety and efficacy of remestemcel-L in participants with ARDS due to coronavirus infection 2019 (COVID-19).
- Trial name
- NCT04366830
- Testing
- Remestemcel-L
- Where
- United States
- Sponsor
- Mesoblast International Sàrl
Moderate COVID-19 Pneumonia, Severe COVID-19 Pneumonia, Pneumonia, Viral
COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients
Due to the limitations of COVID-19 treatment and in the absence of licensed antiviral for COVID-19, the historical choice of therapeutic convalescent plasma (CP) is considered especially against RNA viruses .It was known that…
- Trial name
- NCT04474340
- Testing
- COVID-19 Convalscent Plasma
- Where
- Kuwait
- Volunteers
- 300 people
- Sponsor
- Ministry of Health, Kuwait